Human and mouse targeting peptides identified by phage display
CA 2730627 C · Owner: Board Of Regents, The University Of Texas System · Inventors: Pasqualini, Renata; Arap, Wadih
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention concerns methods and compositions for in vivo and in vitro targeting. A large number of targeting peptides directed towards human organs tissues or cell types are disclosed. The peptides are of use for targeted delivery of therapeutic agents including but not limited to gene therapy vectors. A novel class of gene therapy vectors is disclosed. Certain of the disclosed peptides have therapeutic use for inhibiting angiogenesis inhibiting tumor growth, inducing apoptosis inhibiting pregnancy or inducing weight loss. Methods of identifying novel targeting peptides in humans as well as identifying endogenous receptor- ligand pairs are disclosed. Methods of identifying novel …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 7, 2001 and granted April 30, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended September 7, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 7, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.